U.S., June 9 -- ClinicalTrials.gov registry received information related to the study (NCT07632079) titled 'Hypofractionated Definitive Chemoradiotherapy for Oesophageal Cancer' on April 13.
Brief Summary: The goal of this clinical trial is to learn if hypofractionation of definitive chemoradiotherapy can treat patients with locally advanced esophageal cancer. The main question it aims to answer is if this treatment is feasible and safe. We also want to investigate the toxicity, in particular the radiation-induced lymphopenia.
Normally, definitive chemoradiotherapy for patients with locally advanced esophageal cancer consist of 28 fractions of 1.8 Gy with concurrent 6 cycles of carboplatin and paclitaxel in 5.5 weeks. In this study, parti...